Sandoz Files Anti-Dumping Complaint Over Chinese Amoxicillin Imports
Zurich: Swiss generic drugmaker Sandoz filed a draft anti-dumping complaint with the European Commission over Chinese imports of the antibiotic ingredient amoxicillin, part of the penicillin family, the company said on Thursday.
Sandoz says it has the only major remaining vertically integrated production network for penicillins in Europe.
Sandoz says Chinese market-distorting behaviours include sustained below-cost pricing, state subsidies and concentration of global capacity in China.
Chief Executive Richard Saynor said Europe risks losing antibiotic manufacturing capacity, saying that up to 90% of global antibiotic active ingredients are now produced outside Europe.
"Safeguarding antibiotic supply is not only a health policy issue, but a question of economic security and strategic trade policy. Europe must act now to safeguard independent supply in years to come," Saynor said in the statement.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.